Table 1.
Baseline characteristics of the study cohort (n = 36,136), stratified separately by vaccination status and PCR-confirmed SARS-CoV-2 infection status.
| COVID-19 vaccination status* | SARS-CoV2 infection status | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unvaccinated (n = 2339) |
ChAdOx1 primary schedule | BNT162b2 primary schedule | BNT162b2 booster dose (n = 17,799) |
mRNA-1273 booster dose** (n = 5410) |
No positive PCR test (n = 29,161) |
Positive PCR test (n = 6975) |
|||||
| One dose only (n = 1254) |
Two doses (n = 5309) |
Three doses (n = 112) |
One dose only (n = 319) |
Two doses (n = 1731) |
Three doses (n = 1633) |
||||||
| Incident category | |||||||||||
| Arterial Thrombosis | 960 (41.0%) | 573 (45.7%) | 2562 (48.3%) | 67 (59.8%) | 89 (27.9%) | 651 (37.6%) | 707 (43.3%) | 9229 (51.9%) | 2364 (43.7%) | 14,149 (48.5%) | 3143 (45.1%) |
| Haemorrhagic events | 252 (10.8%) | 81 (6.5%) | 431 (8.1%) | 10 (8.9%) | 47 (14.7%) | 225 (13.0%) | 184 (11.3%) | 1890 (10.6%) | 684 (12.6%) | 3079 (10.6%) | 748 (10.7%) |
| Idiopathic thrombocytopenic purpura | 20 (0.9%) | 10 (0.8%) | 32 (0.6%) | < 5 | < 5 | 34 (2.0%) | 39 (2.4%) | 86 (0.5%) | 35 (0.6%) | 207 (0.7%) | 56 (0.8%) |
| Ischaemic Stroke | 288 (12.3%) | 189 (15.1%) | 768 (14.5%) | Masked | 39 (12.2%) | 226 (13.1%) | 127 (7.8%) | 2085 (11.7%) | 551 (10.2%) | 3548 (12.2%) | 762 (10.9%) |
| Myocardial Infarction | 250 (10.7%) | 145 (11.6%) | 553 (10.4%) | Masked | Masked | 165 (9.5%) | 120 (7.3%) | 1,650 (9.3%) | 628 (11.6%) | 2949 (10.1%) | 624 (8.9%) |
| Thrombocytopenia | 12 (0.5%) | 7 (0.6%) | 26 (0.5%) | < 5 | < 5 | 20 (1.2%) | 28 (1.7%) | 65 (0.4%) | 26 (0.5%) | 158 (0.5%) | 35 (0.5%) |
| Venous thromboembolic events | 557 (23.8%) | 249 (19.9%) | 937 (17.6%) | 14 (12.5%) | 110 (34.5%) | 410 (23.7%) | 428 (26.2%) | 2794 (15.7%) | 1122 (20.7%) | 5071 (17.4%) | 1607 (23.0%) |
| Sex | |||||||||||
| Female | 1078 (46.0%) | 603 (48.1%) | 2701 (50.9%) | 67 (59.8%) | 155 (48.6%) | 840 (48.5%) | 748 (45.8%) | 8564 (48.1%) | 2271 (42.0%) | 13,697 (47.0%) | 3426 (49.1%) |
| Male | 1261 (53.9%) | 651 (51.9%) | 2608 (49.1%) | 45 (40.2%) | 164 (51.4%) | 891 (51.5%) | 885 (54%) | 9235 (51.9%) | 3139 (58.0%) | 15,464 (53.0%) | 3549 (50.9%) |
| Age band (years) | |||||||||||
| 16–29 | 141 (6.0%) | 10 (0.8%) | 40 (0.8%) | < 5 | 41 (12.9%) | 162 (9.4%) | 21 (1.3%) | 76 (0.4%) | 89 (1.6%) | 377 (1.3%) | 211 (3.0%) |
| 30–39 | 170 (7.3%) | 36 (2.9%) | 139 (2.6%) | < 5 | 41 (12.9%) | 173 (10.0%) | 30 (1.8%) | 204 (1.1%) | 177 (3.3%) | 676 (2.3%) | 313 (4.5%) |
| 40–49 | 213 (9.1%) | 87 (6.9%) | 372 (7.0%) | < 5 | 41 (12.9%) | 156 (9.0%) | 76 (4.7%) | 467 (2.6%) | 507 (9.4%) | 1397 (4.8%) | 555 (8.0%) |
| 50–59 | 360 (15.4%) | 143 (11.4%) | 756 (14.2%) | Masked | 36 (11.3%) | 190 (11.0%) | 206 (12.6%) | 1346 (7.6%) | 1519 (28.1%) | 3569 (12.2%) | 1038 (14.9%) |
| 60–69 | 386 (16.5%) | 194 (15.5%) | 837 (15.8%) | Masked | 28 (8.8%) | 188 (10.9%) | 405 (24.8%) | 3068 (17.2%) | 1698 (31.4%) | 5576 (19.1%) | 1285 (18.4%) |
| 70–79 | 475 (20.3%) | 230 (18.3%) | 967 (18.2%) | 32 (28.6%) | 87 (27.3%) | 645 (37.3%) | 578 (35.4%) | 6609 (37.1%) | 808 (14.9%) | 8881 (30.5%) | 1599 (22.9%) |
| 80–89 | 424 (18.1%) | 376 (30.0%) | 1519 (28.6%) | 40 (35.7%) | 34 (10.7%) | 162 (9.4%) | 284 (17.4%) | 4943 (27.8%) | 453 (8.4%) | 6806 (23.3%) | 1463 (21.0%) |
| 90+ | 170 (7.3%) | 178 (14.2%) | 679 (12.8%) | 15 (13.4%) | 11 (3.4%) | 55 (3.2%) | 33 (2.0%) | 1086 (6.1%) | 159 (2.9%) | 1879 (6.4%) | 511 (7.3%) |
| Deprivation status | |||||||||||
| 1 (most deprived) | 690 (29.5%) | 323 (25.8%) | 1354 (25.5%) | 11 (9.8%) | 93 (29.2%) | 464 (26.8%) | 337 (20.6%) | 3165 (17.8%) | 1156 (21.4%) | 5882 (20.2%) | 1739 (24.9%) |
| 2 | 563 (24.1%) | 282 (22.5%) | 1156 (21.8%) | 28 (25.0%) | 72 (22.6%) | 343 (19.8%) | 348 (21.3%) | 3466 (19.5%) | 1272 (23.5%) | 6019 (20.6%) | 1557 (22.3%) |
| 3 | 382 (16.3%) | 226 (18.0%) | 1042 (19.6%) | 28 (25.0%) | 57 (17.9%) | 323 (18.7%) | 307 (18.8%) | 3498 (19.7%) | 1008 (18.6%) | 5692 (19.5%) | 1252 (17.9%) |
| 4 | 379 (16.2%) | 207 (16.5%) | 884 (16.7%) | 24 (21.4%) | 48 (15.0%) | 311 (18.0%) | 290 (17.8%) | 3744 (21.0%) | 950 (17.6%) | 5725 (19.6%) | 1164 (16.7%) |
| 5 (least deprived) | 325 (13.9%) | 216 (17.2%) | 873 (16.4%) | 21 (18.8%) | 49 (15.4%) | 290 (16.8%) | 351 (21.5%) | 3926 (22.1%) | 1024 (18.9%) | 5843 (20.0%) | 1263 (18.1%) |
| Number of previous COVID-19 tests | |||||||||||
| 0 | 1712 (73.2%) | 923 (73.6%) | 3830 (72.1%) | 79 (70.5%) | 207 (64.9%) | 1230 (71.1%) | 1076 (65.9%) | 14,259 (80.1%) | 4215 (77.9%) | 23,459 (80.4%) | 4228 (60.6%) |
| 1 | 311 (13.3%) | 147 (11.7%) | 749 (14.1%) | 11 (9.8%) | 55 (17.2%) | 271 (15.7%) | 273 (16.7%) | 2127 (12.0%) | 791 (14.6%) | 3474 (11.9%) | 1302 (18.7%) |
| 2–4 | 230 (9.8%) | 133 (10.6%) | 513 (9.7%) | 12 (10.7%) | 39 (12.2%) | 152 (8.8%) | 222 (13.6%) | 999 (5.6%) | 331 (6.1%) | 1716 (5.9%) | 935 (13.4%) |
| 5–9 | 69 (2.9%) | 42 (3.3%) | 163 (3.1%) | 10 (8.9%) | 8 (2.5%) | 31 (1.8%) | 46 (2.8%) | 229 (1.3%) | 52 (1.0%) | 332 (1.1%) | 328 (4.7%) |
| 10+ | 17 (0.7%) | 9 (0.7%) | 54 (1.0%) | 0 (0%) | 10 (3.1%) | 47 (2.7%) | 16 (1.0%) | 185 (1.0%) | 21 (0.4%) | 180 (0.6%) | 182 (2.6%) |
*Not shown are the 290 that were either on their first, second or third dose of mRNA-1273 under the primary vaccination schedule.
**Includes those who received half-dose of mRNA-1273.